First-line combined Checkpoint Blockade in Patents with MSI-H/dMMR mCRC

被引：0
|
作者：
Klein, Friederike
机构：
来源：
ZEITSCHRIFT FUR GASTROENTEROLOGIE | 2022年 / 60卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：562 / 562
页数：1
相关论文
共 50 条
  • [1] MSI-H/dMMR mCRC: ICIs in the first line?
    Sidaway, Peter
    NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (12) : 748 - 748
  • [2] MSI-H/dMMR mCRC: ICIs in the first line?
    Peter Sidaway
    Nature Reviews Clinical Oncology, 2021, 18 : 748 - 748
  • [3] New first-line therapy for dMMR/MSI-H CRC
    Romero, Diana
    NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (02) : 63 - 63
  • [4] New first-line therapy for dMMR/MSI-H CRC
    Diana Romero
    Nature Reviews Clinical Oncology, 2021, 18 : 63 - 63
  • [5] SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAFV600E-mutant mCRC
    Elez, Elena
    Kopetz, Scott
    Tabernero, Josep
    Bekaii-Saab, Tanios
    Taieb, Julien
    Yoshino, Takayuki
    Manji, Gulam
    Fernandez, Kathrine
    Abbattista, Antonello
    Zhang, Xiaosong
    Morris, Van K.
    FUTURE ONCOLOGY, 2024, 20 (11) : 653 - 663
  • [6] Early treatment discontinuation (ETD) in dMMR/MSI-H metastastic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICIs)
    Andre, T.
    Lonardi, S.
    Lenz, H. J.
    Jensen, L. H.
    Van Cutsem, E.
    Touchefeu, Y.
    Garcia-Carbonero, R.
    Tougeron, D.
    Mendez, G. A.
    Schenker, M.
    de la Fouchardiere, C.
    Limon, M. L.
    Yoshino, T.
    Li, J.
    Manzano Mozo, J. L.
    Cela, E.
    Chen, T.
    Lei, M.
    Jin, L.
    Elez Fernandez, M. E.
    ANNALS OF ONCOLOGY, 2024, 35 : S450 - S451
  • [7] FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma
    Casak, Sandra J.
    Marcus, Leigh
    Fashoyin-Aje, Lola
    Mushti, Sirisha L.
    Cheng, Joyce
    Shen, Yuan-Li
    Pierce, William F.
    Her, Leah
    Goldberg, Kirsten B.
    Theoret, Marc R.
    Kluetz, Paul G.
    Pazdur, Richard
    Lemery, Steven J.
    CLINICAL CANCER RESEARCH, 2021, 27 (17) : 4680 - 4684
  • [8] Molecular Subtyping of dMMR/MSI-H Tumors
    Sorscher, Steven
    JCO PRECISION ONCOLOGY, 2017, 1
  • [9] Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States
    Aguiar-Ibanez, Raquel
    Hardern, Chloe
    van Hees, Frank
    Lee, Dawn
    Patel, Anubhav
    Chhabra, Nitika
    Baluni, Gargi
    Amonkar, Mayur
    Lai, Yizhen
    Xu, Ruifeng
    Massaad, Rachid
    Fogelman, David
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 469 - 480
  • [10] Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers
    Fuca, Giovanni
    Cohen, Romain
    Lonardi, Sara
    Shitara, Kohei
    Elena Elez, Maria
    Fakih, Marwan
    Chao, Joseph
    Klempner, Samuel J.
    Emmett, Matthew
    Jayachandran, Priya
    Bergamo, Francesca
    Diez Garcia, Marc
    Mazzoli, Giacomo
    Provenzano, Leonardo
    Colle, Raphael
    Svrcek, Magali
    Ambrosini, Margherita
    Randon, Giovanni
    Shah, Aakash Tushar
    Salati, Massimiliano
    Fenocchio, Elisabetta
    Salvatore, Lisa
    Chida, Keigo
    Kawazoe, Akihito
    Conca, Veronica
    Curigliano, Giuseppe
    Corti, Francesca
    Cremolini, Chiara
    Overman, Michael
    Andre, Thierry
    Pietrantonio, Filippo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (02)
12345